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Abstract The cytochromes P450 are a key group of enzymes 
involved in the metabolism of xenobiotics and several biologically 
active endogenous compounds. The expression of CYP3A5 has 
been identified by reverse transcriptase-polymerase chain reac- 
tion in human pituitary gland and shown by immunohistochemis- 
try to be localized to growth hormone containing cells of the 
anterior pituitary gland. This is the first direct identification of 
an individual P450 subfamily in the pituitary gland and the pres- 
ence of CYP3A in the pituitary gland may play a role in regulat- 
ing growth hormone secretion. 
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!. Introduction 
The P450s are a multi-gene family of constitutive and induc- 
ible enzymes which play a central role in the oxidative metabo- 
lism of a diverse range of xenobiotics and a variety of biologi- 
cally active endogenous compounds [14].  In general terms 
there are two broad classes of  mammal ian P450s: a large class 
of P450s which are primarily involved in xenobiotic metabol ism 
and a second smaller group specifically involved in steroid 
hormone synthesis. The xenobiotic metabolizing P450 families 
(CYPI ,  CYP2 and CYP3) are expressed mainly in tissues ex- 
posed to environmental  nd dietary chemicals [5-7]. They may, 
however, also have a role in cell regulation in view of their 
involvement in the metabol ism of physiological chemicals ac- 
tive in inter- and intra-cellular signaling, including steroid 
hormones, eicosanoids and fatty acids [8]. 
The pituitary gland has a central role in homeostasis and 
there is evidence in the rat that the pituitary contains P450 
[9 11], the activity of which contributes to the regulation of 
pituitary polypeptide hormone secretion [11 14]. 
In this study we have identified the cell-specific expression 
of CYP3A5 in growth hormone containing cells of the human 
anterior pituitary gland. 
2. Materials and methods 
2.1. Tissue 
Twelve pituitary glands (5 males, 7 females, age range 62 84 years) 
were obtained, with permission, from autopsies performed in the De- 
partment of Pathology, University of Aberdeen, within 24 h of death. 
None of the patients had any evidence of pituitary disease, other endo- 
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crine disease or degenerative n urological disease. Each pituitary gland 
was divided into two portions: one part was frozen in liquid nitrogen 
and used for RT-PCR and the other part was fixed in 10% neutral- 
buffered formalin for 24 h, then embedded in wax and used for immu- 
nohistochemistry. 
2.2. RT-PCR 
Total RNA was extracted using essentially the method of 
Chomczynski and Sacchi [15]. The recovered RNA pellet was resus- 
pended in 100 /~1 distilled water pretreated with 0.1% (v/v) DEPC 
(Sigma, Poole, UK). Single stranded cDNA was synthesised from the 
RNA using oligo (dTh5 (Promega, Southampton, UK) with the follow- 
ing reaction conditions: RNA (20/~1), 50 mM KCI, 10 mM MgC12, 0.5 
mM spermidine, 10 mM dithiothreitol (Sigma), 40 units human placen- 
tal ribonuclease inhibitor (Promega), 0.125 mM each of dATER dCTER 
dGTP and dTTP (Promega), 18 units avian myeloblastosis virus reverse 
transcriptase (Promega) and 0.5 mg oligo (dTh5 primer (Promega) in 
50 mM Tris-HCl, pH 8.3. cDNA was then synthesised at42°C for 60 
rain and the synthesis was stopped by heating the reaction mixture to 
80°C for 5 min. 
CYP3A primers were designed to recognise sequences common to 
CYP3A4, CYP3A5 and CYP3A7 and to give a product of 714 bp in 
each case [16-18]. The specific sequences are located on exon 7 and exon 
11 of CYP3A4 [19]. The primers were synthesised and purified with 
HPLC by Oswel DNA Service (Edinburgh, UK) with the following 
sequences: 
Forward primer 5'-GGC CTA CAG CAT GGA TGT GAT CAC-3' 
(CYP3A4, nt 621 644; CYP3A5, nt 618 641; CYP3A7, nt 534-557) 
Reverse primer 5'-GAG GAA CTT CTC AGG CTC TGT CCA G-3' 
(CYP3A4, nt 1311-1335; CYP3A5, nt 1308-1332; CYP3A7, nt 1224- 
1248) 
PCR using the hot start echnique was carried out in a 100/A reaction 
volume consisting of 10 mM Tris-HCl, pH 9.0, 50 mM KCI, 0.1% 
Triton X-100, 2.5 mM MgCI,, 0.4 mM each of dATER dCTP, dGTP and 
dTTER 0.5 U Taq DNA polymerase (Promega), 2/11 cDNA and 50 pmol 
of each primer. 30 cycles of amplification were performed using the 
following conditions: 94°C for 1 min (denaturation); 53°C for 0.5 min 
(annealing); 72°C for 1 min (extension); and a final further 2 min 
extension at 72°C. Both positive and negative controls were included 
in the PCR. The positive control was a 2.3 kb CYP3A4 cDNA (isolated 
from a human liver cDNA library in our laboratories) which had been 
cloned into 2gtl 1. The negative control was DEPC treated water in 
place of template cDNA. After PCR 5/11 of the PCR product was 
electrophoresed on a 1.2% agarose gel and stained with ethidium bro- 
mide. The PCR product was purified with a Wizard miniprep DNA 
purification system (Promega) used according to the manufacturers 
instructions and analysed by Southern hybridization and direct se- 
quencing. Southern hybridization was carried out according to Sam- 
brook et al. [20] using a probe generated by PCR from the CYP3A4 
plasmid as described above. The probe was labeled with 32p by nick 
translation using a kit supplied by Amersbam International (Amer- 
sham, UK). PCR products were sequenced using a modification of the 
direct dideoxy sequencing technique of Sanger et al. [21] with a T7 
sequencing kit (Pharmacia, Milton Keynes. UK) used according to the 
manufacturers protocol with dimethyl sulfoxide used as denaturant. 
2.3. Antibodies 
CYP3A was identified with monoclonal antibody HP3 which recog- 
nises all known forms of human hepatic CYP3A [22]. Rabbit polyclonal 
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antibodies to the different anterior pituitary hormones (adrenocorti- 
cotrophic hormone, follicle stimulating hormone, growth hormone, 
luteinising hormone, prolactin and thyroid stimulating hormone) were 
obtained from the National Institutes of Health, Bethesda USA. Horse- 
radish peroxidase conjugated rabbit anti-mouse immunoglobulin, 
horseradish peroxidase conjugated swine anti-rabbit and FITC conju- 
gated swine anti-rabbit mmunoglobulins were purchased from Dako 
Ltd, High Wycombe, UK. 
2.4. Immunohistochemistry 
Immunohistochemistry was performed on sections of formalin fixed 
wax embedded pituitary gland using an immunoperoxidase technique 
as previously described [23]. Formalin fixed wax embedded sections of 
normal iver were used as a positive control [24]. Briefly, endogenous 
peroxidase was blocked and the sections were then sequentially incu- 
bated with the different primary antibodies followed by the relevant 
peroxidase conjugated second layer antibody. After each antibody in- 
cubation excess unbound antibody was removed by washing with TBS, 
and sites of antibody binding were identified using 3,Y-diaminobenzid- 
ine (Sigma) as the peroxidase ubstrate. 
CYP3A and pituitary hormones were co-localized by double staining 
on the same section using immunofluorescence for antibodies to ante- 
rior pituitary hormones and immunoperoxidase with monoclonal nti- 
body HP3 for CYP3A. A second layer FITC conjugated swine 
anti-rabbit immunoglobulin (1/10 in TBS, Dako) was used for the 
immunofluorescence detection of anterior pituitary hormone im- 
munoreactivity. Double labeled sections were examined with transmit- 
ted light and epi-fluorescence microscopy (Nikon, London, UK) with 
a filter block (B2, Nikon) for FITC (excitation 450~,90 nm, dichroic 
mirror 510 nm and emission filter 520 nm). 
3. Results 
3.1. RT-PCR 
The RNA isolated from each pituitary gland displayed min- 
imal evidence of degradation as judged by agarose gel electro- 
phoresis following denaturation by formaldehyde (data not 
shown). Analysis of the PCR product by visual inspection of 
an ethidium bromide stained agarose gel showed a clear single 
band of the predicted size (714bp) in 6 of the 12 pituitary 
samples (Fig. 1). Southern transfer and hybridization, however, 
showed the presence of an amplification product of the correct 
size in all 12 samples (Fig. 2). Sequencing ofthe individual PCR 
products howed identity with CYP3A5. 
3.2. Immunohistochemistry 
All 12 pituitary glands demonstrated positive immunoreac- 
tivity for CYP3A using monoclonal ntibody HP3, with strong 
cytoplasmic (i.e. non-nuclear) immunostaining of adiscrete and 
major population of cells within the anterior pituitary gland. 
The posterior pituitary gland did not immunostain for CYP3A. 
In the pituitary gland the distribution ofCYP3A immunostain- 
ing with HP3 was similar to the pattern of immunoreactivity 
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Fig. 1. Ethidium bromide stained agarose gel of pituitary PCR prod- 
ucts. Lanes 1, 8 and 15 molecular weight markers, lanes 2 7 pituitary 
samples, lanes 9-14 pituitary samples, lane 16 negative control (DEPC- 
treated water), lane 17 positive control (CYP3A4 plasmid). 
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observed for growth hormone. Double immuno-labelling of the 
pituitary sections for both CYP3A and growth hormone con- 
firmed that CYP3A and growth hormone were co-localized to 
the same cells (Fig. 3). 
4. Discussion 
In this study we have identified the expression of P450 
CYP3A5 within the human pituitary gland and localized its 
immunoreactivity to growth hormone containing cells of the 
anterior pituitary. Although there is circumstantial evidence for 
P450 in rat pituitary, namely a carbon monoxide-binding spec- 
trum and characteristic monooxygenase activities [9-11], this is 
the first direct identification of an individual P450 subfamily in 
pituitary, and the first evidence for P450 expression i  human 
pituitary. The human CYP3A gene subfamily of xenobiotic 
metabolising P450s contains three known forms, CYP3A4, 
CYP3A5 and CYP3A7; are capable of metabolising a wide 
range of xenobiotics and endogenous compounds and are ex- 
pressed in both hepatic and extra-hepatic tissues [6,25]. 
CYP3A5 although only expressed in about 25% of livers has 
been shown to be much more frequently expressed in extra- 
hepatic tissues and indeed has been shown to be the major form 
of CYP3A expressed in kidney [26,27]. 
The strategy we have adopted to identify the CYP3A ex- 
pressed in human pituitary has been to perform RT-PCR using 
primers which recognise sequences common to all known 
human CYP3A forms and then to sequence the PCR product. 
A sequence identical to CYP3A5 was obtained from each PCR 
product. Due to the small size of the pituitary gland, it was not 
possible to confirm the molecular weight of the CYP3A-im- 
munoreactive pituitary protein by immunoblotting. 
11 12 13 14 15 
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Fig. 2. Autoradiogram ofCYP3A PCR products following Southern transfer and hybridization. Lanes 1 6 pituitary samples, lanes 7 and 14 negative 
controls (DEPC-treated water), lanes 8 13 pituitary samples, lane 15 positive control (CYP3A4 plasmid). The individual pituitary samples are in 
the same consecutive order as in Fig. 1. 
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Fig. 3. Double immunolabelling of anterior pituitary gland for CYP3A 
and growth hormone. (a) CYP3A immunoreactivity with monoclonal 
antibody HP3 using immunoperoxidase staining. (b) Growth hormone 
immunoreactivity with a polyclonal antibody using immunofluores- 
cence staining. The same section is viewed by (a) bright field microscopy 
and (b) epi-fluorescence microscopy to show that both CYP3A and 
growth hormone are co-localized in anterior pituitary cells. (To facili- 
tate the comparison arrows indicate two cells which are the same in 
both photographs). Magnification for (a) and (b) x 1000. 
CYP3A was localized specifically to growth hormone con- 
taining cells of the anterior pituitary gland. Here it may play 
a role in regulating rowth hormone secretion, since the release 
of growth hormone from rat pituitary somatotrophs in vitro is 
inhibited by broad spectrum cytochrome P450 inhibitors [14] 
and stimulated by epoxyeicosatrienoic acid metabolites of ara- 
chidonic acid produced by P450 [12,13]. Moreover, these meta- 
bolites can also be metabolically inactivated by P450 [4]. The 
presence of a steroid-hydroxylating form of P450 in the pitui- 
tary gland also provides a potential mechanism for limiting the 
steroid hormone feedback regulation of growth hormone secre- 
tion [28]. 
In conclusion, the concerted use of RT-PCR and immunohis- 
tochemistry has identified and localized cytochrome P450 
CYP3A5 specifically to the growth hormone containing cells of 
the human anterior pituitary gland. 
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